Suchergebnisse - "Wiviott, Stephen D."

PubPharm (31)

1

Natriuretic peptides, body mass index and heart failure risk : Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61

enthalten in: European journal of heart failure | 2024

von Patel, S. | Morrow, D. | Bellavia, A. | +13

2

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes

enthalten in: Diabetes care | 2023

von Moura, F. | Berg, D. | Bellavia, A. | +10

3

Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus

enthalten in: Journal of the American College of Cardiology | 2023

von Berg, D. | Moura, F. | Bellavia, A. | +11

CommentIn: J Am Coll Cardiol. 2023 Jun 27;81(25):2403-2405. - PMID 37344041

4

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes : A Secondary Analysis of the DECLARE-TIMI 58 Trial

enthalten in: JAMA cardiology | 2023

von Zelniker, T. | Wiviott, S. | Mosenzon, O. | +17

5

Effects of dapagliflozin on hospitalisations in people with type 2 diabetes : post-hoc analyses of the DECLARE-TIMI 58 trial

enthalten in: The lancet. Diabetes & endocrinology | 2023

von Schechter, M. | Wiviott, S. | Raz, I. | +16

CommentIn: Lancet Diabetes Endocrinol. 2023 Apr;11(4):218-219. - PMID 36878241

6

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose : Post Hoc Analyses From DECLARE-TIMI 58

enthalten in: Diabetes care | 2023

von Pollack, R. | Raz, I. | Wiviott, S. | +13

7

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes : Post Hoc Analyses From the DECLARE-TIMI 58 Trial

enthalten in: Diabetes care | 2022

von Mosenzon, O. | Raz, I. | Wiviott, S. | +18

8

Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes : A Prespecified Secondary Analysis of a Randomized Clinical Trial

enthalten in: JAMA cardiology | 2022

von Oyama, K. | Raz, I. | Cahn, A. | +9

9

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

enthalten in: European heart journal | 2022

von Oyama, K. | Raz, I. | Cahn, A. | +14

CommentIn: Eur Heart J. 2021 Oct 07;:. - PMID 34618015

10

Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure : Observations From DECLARE-TIMI 58 Trial

enthalten in: Circulation | 2022

von Furtado, R. | Raz, I. | Goodrich, E. | +17